骨ルポ
ANZBMS 2019 レポート
浜谷 絵里（北海道大学大学院歯学研究科口腔病態学講座 歯科麻酔学教室）
In 29th ANZBMS Annual Scientific Meeting, a lot of excellent research were presented. We report the regulation of osteoadherin (also termed osteomodulin) in osteoblasts. Osteoadherin is encoded by the Omd gene and is a keratan sulfate proteoglycan of the class II subfamily of SLRPs. Osteoadherin is highly expressed in mineralized tissues, including bone and dentin; however, it's precise roles remain unknown. We investigated the Omd expression levels and the effects of over‑ and under‑expression of osteoadherin in osteoblastic cells. Omd mRNA expression increased with osteoblast differentiation in MC3T3‑E1 cells. In C2C12 cells, Omd mRNA expression was induced by bone morphogenetic protein (BMP)2. Reporter assays similarly demonstrated activation of the Omd gene promoter following co‑transfection with Smad1 and Smad4, which are intracellular signaling molecules of the BMP2 signaling pathway. Overexpression of Omd increased the viability and decreased caspase 3/7 activity in MC3T3‑E1 cells. By contrast, following transfection with small interfering RNA for Omd, viable cell numbers were decreased and caspase 3/7 activity was increased. Furthermore, overexpression of Omd reduced the expression of CCN family 2 in these cells. These results demonstrate that Omd expression is regulated during osteoblast differentiation, and that the protein product osteoadherin serves roles in the apoptosis and growth of osteoblast cells. I enjoyed presenting my research and learning from related posters.
紹介演題 [1]
A study of the early effect of an optimal dose of NSAIDs in treatment of early axial SpA patients
キーワード
NSAIDs, SpA, radiographic progression
研究グループ
Fatma Fayed
- Alexandria university
サマリー＆コメント
They evaluated the early effect of continuous treatment with optimum dose of NSAIDs on disease activity and radiographic progression of newly diagnosed axial spondyloarthritis (axSpA). A six-week prospective study on thirty consecutive newly diagnosed active axSpA patients. All patients were assessed at baseline visit, a follow-up visit after 2 weeks, and after 6 weeks of treatment with a continuous optimal dose of NSAIDs. Disease activity was assessed by determining BASDAI and ASDAS, while functional assessment was evaluated by using BASFI. Spinal mobility was assessed by the mean improvement in BASMI. Magnetic Resonance Imaging of sacroiliac joints was taken at baseline and at the end of the study and was evaluated according to Berlin scoring method. They observed improvement in Berlin MRI score, laboratory markers, as well as other clinical parameters including disease activity, spinal mobility, and pain scale.
紹介演題 [2]
Atypical femoral fractures – are bisphosphonates the only culprit
キーワード
bisphosphonates, atypical femoral fracture, osteoporosis
研究グループ
Kara Nowak
- Rheumatology and General Medicine, Eastern Health, Box Hill, Victoria, Australia
サマリー＆コメント
They conducted a retrospective review of cases of atypical femoral fractures presenting to two metropolitan hospitals over an 8 year period. All fractures were confirmed by a radiologist and an orthopedic surgeon using the American Society for Bone and Mineral Research Task Force 2013 revised case definition of atypical femoral fractures1. The result was that 27 patients presented with atypical femoral fractures during the study period. 20 patients had unilateral atypical femoral fractures, and 7 had bilateral atypical femoral fractures or unilateral atypical femoral fracture with impending fracture on the contralateral side. Bisphosphonates were the largest risk factor for the development of an atypical femoral fracture with 23 patients having had prior exposure.